# Critical Evaluation of NF-κB–Complement Cascade Hypotheses
---
## Hypothesis 1: Direct NF-κB Transcriptional Regulation of C1q Genes
### Weak Links
- **Promoter presence ≠ functional regulation**: Identification of κB sites in promoters demonstrates *possibility*, not *mechanism*. Functional validation in the specific sevoflurane context is absent.
- **Causal gap in cited evidence**: PMID:25620734 establishes TNF-α–induced C1q as NF-κB–dependent, but this does not establish direct promoter binding. The pathway could involve intermediate transcription factors (e.g., IRF, CREB).
- **Cell-type specificity unaddressed**: C1q expression in microglia vs. astrocytes may be governed by distinct regulatory programs. The hypothesis assumes universal applicability across cell types.
### Counter-Evidence
- **Alternative transcriptional regulators dominate**: C1q promoters contain binding sites for AP-1, PU.1, and Sp1; NF-κB may play permissive rather than instructive roles.
- **Constitutively expressed C1q**: Under homeostatic conditions, C1q is expressed without apparent NF-κB dependence, suggesting context-dependent regulation.
### Falsifying Experiments
1. **ChIP-seq for p65/RelA after sevoflurane exposure** showing no enrichment at C1QA/C1QB/C1QC promoters would substantially weaken (not definitively falsify, given redundancy with p50/p52) this hypothesis.
2. **Luciferase reporter assay with κB site mutagenesis**: If mutant promoters retain full sevoflurane-induced activity, direct regulation is falsified.
3. **Microglia-specific IKKβ deletion**: If C1q upregulation persists after sevoflurane, NF-κB is not required in microglia, suggesting paracrine or indirect mechanisms.
**Revised Confidence: 0.55** (Downgraded from 0.72 due to speculative promoter binding claims and reliance on indirect evidence)
---
## Hypothesis 2: Astrocyte IL-1β as Paracrine Mediator
### Weak Links
- **Missing direct IL-1β → C1q evidence**: The cited IL-1β–C3 link (PMID:10899056) does not directly extend to C1q. C1q and C3 are regulated by distinct pathways; this inference is unsupported.
- **Temporal and spatial constraints**: IL-1β secretion and microglial responsiveness require precise spatial coupling. Sevoflurane-induced astrocyte-microglia contact zones are not established.
- **Redundant cytokine networks**: TNF-α, IL-6, and ATP (via P2X7R) also induce microglial complement. IL-1β may be one of several parallel inputs.
### Counter-Evidence
- **IL-1β receptor (IL-1R1) expression in microglia is variable**: Not all microglia subsets respond equivalently to IL-1β; baseline expression may be low in the experimental model used.
- **Astrocyte IL-1β may be downstream of microglial activation**: The directionality assumed here may be reversed in sevoflurane models where microglia are directly affected.
### Falsifying Experiments
1. **Anakinra or IL-1R1 antagonist (IL-1RA) administration**: If C1q/C3 expression is unaffected, IL-1β is not the critical mediator.
2. **Conditional IKKβ deletion in GFAP+ astrocytes** combined with rescued IL-1β supplementation to determine if effects are IL-1β–dependent or due to other astrocyte-derived factors.
3. **IL-1β neutralizing antibodies in sevoflurane-exposed hippocampal slices**: Direct demonstration of C1q suppression.
**Revised Confidence: 0.52** (Downgraded from 0.68; IL-1β→C1q inference is unsupported, and alternative cytokine pathways are plausible)
---
## Hypothesis 3: Microglial Priming via NF-κB–Dependent Complement Biosynthesis
### Weak Links
- **DAM signature is correlative**: Upregulation of complement genes in the Trem2-independent DAM cluster (PMID:28872028) is an association. Whether NF-κB drives both the DAM phenotype *and* complement genes, or whether these are parallel consequences of a common trigger, is unresolved.
- **Mechanistic ambiguity**: NF-κB could regulate complement indirectly via intermediate genes (e.g., cytokines, transcription factors) rather than directly.
- **Synaptic C1q deposition mechanism**: C1q protein must be translated, folded, and secreted. The link from microglial transcriptional activation to synaptic accumulation is assumed, not demonstrated.
### Counter-Evidence
- **DAM microglia may not be the primary C1q source**: Astrocytes and neurons can also produce C1q; microglial NF-κB activation does not guarantee synaptic C1q deposition.
- **C1q can be pre-formed and stored**: Some immune cells contain intracellular C1q pools; transcriptional regulation may not be the